Skip to Main Content
David Lu
David Lu

David Lu

Partner
Boston
+1.617.261.3252
Email David Lu @ David.Lu@klgates.com
Download V-Card
Download David Lu PDF (English)

David Lu is a partner in the firm's Intellectual Property practice. David focuses his practice on patent prosecution, strategic intellectual property counseling, and due diligence for life science industries. He has designed global patent strategies in the field of pharmaceuticals and biotechnology, and managed large patent portfolios for a variety of clients. David's clients range from international corporations, mid-sized biotech companies, to venture capital funded startups. 

David has handled matters in numerous technology areas, including cancer therapies, genome technologies, gene therapies, antibodies and antibody-drug conjugates, mRNA technologies, siRNA drugs, personalized medicine, small molecules, diagnostic methods, medical devices, and laboratory instruments. By identifying each client's technology strengths and business goals, David provides customized and creative legal solutions.

Prior to joining the firm, David served as a partner and the co-lead of the life sciences group at a US law firm. Prior to his legal career, David conducted cancer research at Dana-Farber Cancer Institute and Harvard Medical School and studied RNA biology and virology at Duke University.

  • Recognized by Chambers USA for Intellectual Property in Massachusetts, 2024
  • Selected to Massachusetts Rising Stars for Intellectual Property (2019-2023)
  • National Institute of Health (NIH) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship (2007-2008)
  • Member, Boston Intellectual Property Law Association (BIPLA)
  • Member, National Asian Pacific American Bar Association (NAPABA)
  • Member, Asian American Lawyers Association of Massachusetts (AALAM)
  • Member, Duke Boston Regional Board
  • Leadership Councils, Health Care and Life Sciences, Greater Boston Chamber of Commerce
  • “The Three Pillars of Your Patent Prosecution: Innovation, Insights & Strategy,” CenterForce IP Strategy Series, Boston, MA, 15 June 2023
  • Co-author, Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle. Genes Dev. 27(20): 2274-91. (2013)
  • Co-author, Further evidence for BRCA1 communication with the inactive X chromosome. Cell 128(5): 998-1002. (2007)
  • Co-author, Epstein-Barr Virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2(3):e23. (2006)
  • Co-author, Kaposi’s sarcoma associated herpesvirus expresses an array of novel viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. U S A 102(15): 5570-75. (2005)
  • Co-author, Adenovirus VA1 non-coding RNA can inhibit small interfering and microRNA biogenesis and function. Journal of Virology 78(23): 12868-76. (2004)
  • Co-author, Nonsense mediated decay induced by tethered human UPF3B is restricted to the cytoplasm. RNA Biology 1(1): 42-47. (2004)
  • Co-author, Exon junction complexes mediate the enhancing effect of splicing on mRNA expression. Proc. Natl. Acad. Sci. U S A 100(20): 11327-32. (2003)
  • Co-author, Analysis of the stimulatory effect of splicing on mRNA production and utilization in mammalian cells. RNA 9(5): 618-30. (2003)
Additional News & Event Pages
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel